More Videos
|
CNBC'S MOST SHARED
- A Goldman Trading Scandal?
- Rich People With A Death Wish
- Facebook Director Sees 'Billions' in Revenue in 5 Years
- The Threat of Ballooning Pensions
- Lehman CEO: Firm Deserved Bailout or 'Wind Down'
- FedEx Sees Signs of a Turnaround: Report
- Texting And Driving Worse Than Drinking and Driving
- Market's Monday Blues
- Hey, What's Up Doc?
- Judge Gives Control of Jackson Estate to Executors
- March Lows Will Hold — So Buy Equities: Strategists
- Lacoste Runs Full Page Ad With Roddick Loss
- Brandt: Bing, The Little Search Engine That Couldn't
- 5-Star Manager's 5 Top Stocks
- Hey, What's Up Doc?
- Busch: Summertime Blues Hits Investors
- Chadwick: Recession and Scandals Pave the Way for Romney 2012
- Art Cashin: The S&P's 'Head and Shoulders' Number
- Michael Jackson: Death And Taxes
- Second Half: Wait For Pullbacks, Then Buy the Best
- Accused Ex-Goldman Sachs Programmer Out on Bail
- Discover Shares Fall on Word of Stock Offering
- California General Obligation Bond Rating Cut
- GM to Get Final $20 Billlion From US This Year
- World Trade Center Developer Threatens Arbitration
- The Weirdest Currencies on Earth
- Judge Gives Control of Jackson Estate to Executors
- Recession Special: Wine Cheaper Than Water!
RSS FEED
Text Size 
 |
Rick Lee Heart Stent |
]drug-coated stent will not happen in the second quarter. Recently, at least a couple of analysts have been telling clients a decision was getting pushed out until the third quarter and one suggested that Xience won't be launched until Q4. The question now is whether the FDA will make a move before the July 4th holiday. Any bets?
Speaking of stents, a folo-up to my post last week on the analyst report saying that Boston Scientific [BSX
Loading...
()
]is discounting its drug-coated stent when they're bought along with other medical devices the company makes. At first, a BSX spokesman told me the company doesn't publicly talk about such alleged deals. But then Paul Donovan sent me another email last night asking in the subject line, "What were you smoking?" He took me to task for repeating "an unsubstantiated claim we're (BSX) selling stents for $1,100. We sell stents for about double that, and often more."
And as long as we're on the subject of corporate communications I wanted to pass along this anecdote about yesterday's Alzheimer's drug news out of Myriad Genetics[MYGN
Loading...
()
]. My producer, Ruth, had been working with their people to make sure we were in the loop when the biotech company released the highly anticipated late-stage test results. But the relationship-building groundwork was all for naught.
The press release went out before the opening bell on Monday, but we got no heads up or even an email once the release went out to make sure we saw it. I was out of pocket on assignment in Washington, DC, but reachable--as always--via BlackBerry. When Ruth queried the MYGN point-person about the oversight he replied, "We were planning personal outreach to you on positive results. Then when we found out the results were negative, no one thought to make sure you were on the email distribution list."
Oh, and I wasn't smoking anything when I wrote the BSX post. Aside from what I think was a contact high during my freshman year in the USC Trojan Marching Band on a bus returning from a gig, I've never inhaled.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes